Gynaecological clinical trials currently open to patients are listed by cancer type.
More detailed information for each trial is in the printable trial summary.
Many patients with advanced cancers, particularly those with ovarian & bowel cancer, will have a buildup of fluid (ascites) in the abdominal cavity in their final months of life. This causes significant symptoms & distress and has a major impact on quality of life. These patients require regular paracentesis (removal of fluid from the peritoneal cavity) to control their symptoms and it would be relatively straightforward to have a short infusion of bevacizumab (a targeted agent) following a required drainage.
This study will test whether administering bevacizumab into the peritoneal cavity (known as intraperitoneal (IP) administration) will reduce the formation of ascites and delay the time to re-accumulation of ascitic fluid in those patients with chemotherapy resistant ovarian and related cancers who produce malignant ascitic fluid.
There is some evidence to suggest that a single dose of IP bevacizumab can delay the accumulation of ascites for up to 8 weeks and is safe. Subsequent doses of drug may be made available to women who respond to the first dose.
The study will also evaluate changes in the quality of life of these women and look at factors that cause the formation of malignant ascites.
To see if anastrozole (an aromatase inhibitor, also known as Arimidex®) which is a hormonal or anti-oestrogen therapy will help reduce the size of tumours and delay the time to progression, as well as improve symptom control and quality of life, in women with potentially hormone responsive recurrent gynaecological cancers.
Hormonal therapy is widely used to treat a number of cancers with breast cancer being the most common example. Aromatase inhibitors such as anastrozole are considered the most effective drugs to treat women with hormone responsive breast cancers and are approved for this use.
There is evidence that hormonal therapy may also be effective in some women with gynaecological cancers and a variety of different hormonal treatments have been used.Printable Trial Summary
Exercise is now considered an effective treatment in its own right and an important part of overall management of a number of cancers. It improves short-term outcomes during chemotherapy (eg. function, fatigue and quality of life) in breast, colorectal, and haematological cancers, and may assist patients to receive the planned dose of chemotherapy without delay or dose modifications. There is also preliminary data to suggest exercise can improve survival following breast cancer.
The aim of ECHO is to determine the enduring effects on survivorship of an exercise intervention administered in addition to usual care, compared to usual care alone, during first-line chemotherapy for epithelial ovarian, primary peritoneal and fallopian tube cancer.
The current standard treatment for endometrial cancer includes a total hysterectomy involving surgical removal of uterus, fallopian tubes and ovaries. Though highly effective, this treatment carries significant side effects for two groups of women:
- young women who would be left with irrevocable infertility, although they may wish to have children
- women with severe obesity and medical co-morbidities for whom surgery is unsafe because of a high risk of surgical complications.
This trial will access a new approach to the treatment of endometrial cancer, thus sparing women major surgery. Our aim is to find out the effectiveness of Mirena ® (a hormonal intrauterine device), Mirena® with Metformin (an oral antidiabetic drug), and Mirena® with weight loss at getting rid of endometrial cancer and endometrial hyperplasia with atypia. Printable Trial Summary
The OUTBACK Study is now CLOSED for new patient recruitment.
To improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.
The role, if any, of adjuvant chemotherapy is arguably the most important and outstanding question in the management of locally advanced cervical cancer. This international multi-centre phase III trial will test the value of giving women with locally advanced cervical cancer adjuvant chemotherapy following completion of standard chemo-radiation treatment.Printable Trial Summary